Income statement
USD
Annual
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | 782K | 164K |
| Gross Profit | 448K | -69K |
| Operating Income | 284K | -179K |
| EBITDA | 153K | -146K |
| Net Income | 50K | -253K |
| EPS (Diluted) | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rising BioSciences, Inc. (RBII) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +377.8%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue +377.8%, EPS +100.0%, free cash flow +50.0% with operating margin 36.3% and ROIC -851.8%. Valuation is more restrained than many high-expectation growth names at P/E 0.2 and price/sales 0.0. Stock Foundry combines RBII price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RBII
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RBII Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RBII and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$163.7K
-79.1% YoY
FY Net Income
-$253.2K
-608.9% YoY
Free Cash Flow
-$140.7K
-100.1% YoY
Revenue Growth
+377.8%
EPS Growth
+100.0%
Gross Margin
57.3%
Net Margin
6.4%
Income statement
USD
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | 782K | 164K |
| Gross Profit | 448K | -69K |
| Operating Income | 284K | -179K |
| EBITDA | 153K | -146K |
| Net Income | 50K | -253K |
| EPS (Diluted) | — | — |
Balance sheet
USD
| Metric | 2020 | 2019 |
|---|---|---|
| Cash & Equivalents | 48K | 763 |
| Total Assets | 640K | 400K |
| Total Liabilities | 2M | 2M |
| Shareholder Equity | -1M | -1M |
| Total Debt | 1M | 946K |
| Net Debt | 1M | 946K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
59K
+15.5% YoY
Capital Expenditures
81K
-2710466.7% YoY
Free Cash Flow
141K
-100.1% YoY
Key ratios
Gross Margin
57.3%
Operating Margin
36.3%
Net Margin
6.4%
ROE
-4.4%
Debt / Equity
-0.97x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.